Matrix metalloproteinases (MMPs) are family of zinc containing calcium dependent enzymes that have the capacity to degrade almost every component of the ECM in normal as well as in abnormal conditions. MMPs have been found in vertebrates, invertebrates and also plants. The functions of MMPs are intricately regulated by its specific endogenous regulators or the inhibitors known as tissue inhibitor of metalloproteinases (TIMPs) at the time of activation and inhibition of the enzymes. MMPs and TIMPs are involved in the regulation of cell characteristics in normal as well as the state of human morbidity and mortality. There are numerous roles of MMPs and/or TIMPs in normal physiological processes like tissue remodelling and development, wound healing, angiogenesis, immune response and inflammation, cell proliferation and cell signalling that are good. Again, the ugly is the abnormal activity or over expression of MMPs and/or TIMPs that have the distinct role in many disease processes like diabetes, arthritis, fibrosis, cardiovascular diseases and cancer. When the expression of MMPs is altered, it can generate the abnormal degradation of the ECM, thus highlighting MMPs as promising therapeutic targets. Within the ECM, TIMPs inhibit the proteolytic activity of MMPs. TIMPs are important regulators of ECM turnover, inflammation, cell proliferation, tissue remodeling, wound healing and cellular behaviour thereby releasing growth factors beneficial for cellular repair and differentiation. An interruption in the balance between MMPs and TIMPs has been implicated in the progression of several diseases. Such as, the development of chronic degenerative diseases, vascular complication, neurodegeneration, cancer progression and several other diseases. This chapter focuses on the participation of both MMPs and TIMPs in physiological as well as pathological processes and on how their abnormal regulation is associated with several diseases. The inclusion of current strategies and mechanisms of MMP inhibition in the development of new therapies targeting MMPs was also considered.